⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19527163 | 1.00 | — | — | |
| SCHEMBL4077174 | 1.00 | — | — | |
| SCHEMBL9594106 | 1.00 | — | — | |
| SCHEMBL9594097 | 1.00 | — | — | |
| SCHEMBL13497229 | 1.00 | — | — | |
| SCHEMBL4076481 | 1.00 | — | — | |
| SCHEMBL8761261 | 1.00 | — | — | |
| SCHEMBL7993325 | 0.85 | — | — | |
| SCHEMBL22559995 | 0.85 | — | — | |
| SCHEMBL12464625 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10201533-B2 | Substituted quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180028509-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028509-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9861620-B2 | Substituted quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20160304478-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304478-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-9428452-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-08-30 | — | — | US | disclosed |
| US-9428452-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-08-30 | — | — | US | disclosed |
| WO-2013160418-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-10-31 | — | — | WO | disclosed |
| WO-2012137982-A9 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
| WO-2010069979-A1 | PYRAN DERIVATIVES AS CCR3 MODULATORS | NYCOMED GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| US-7560231-B2 | Mannitol and glucitol derivatives | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1431298-B1 | Mannitol and glucitol derivatives | ROCHE DIAGNOSTICS GMBH (DE) | 2006-03-08 | — | — | EP | disclosed |
| US-20040157247-A1 | Mannitol and glucitol derivatives | ROCHE MOLECULAR SYSTEMS, INC (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1431298-A1 | Mannitol and glucitol derivatives | Roche Diagnostics GmbH (DE) | 2004-06-23 | — | — | EP | disclosed |
| EP-1431297-A1 | Mannitol and glucitol derivatives | BOEHRINGER MANNHEIM GMBH (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-5169842-A | OLIGOPHOSPHATES WITH AN ANTIVIRAL ACTION | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | disclosed |